First Trust Advisors LP Has $5.33 Million Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

First Trust Advisors LP increased its stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) by 9.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 672,403 shares of the company's stock after buying an additional 59,601 shares during the quarter. First Trust Advisors LP owned about 0.22% of Amneal Pharmaceuticals worth $5,325,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in AMRX. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Amneal Pharmaceuticals during the 4th quarter valued at about $81,000. Straightline Group LLC acquired a new position in Amneal Pharmaceuticals in the 4th quarter valued at about $92,000. Cibc World Markets Corp purchased a new stake in shares of Amneal Pharmaceuticals during the 4th quarter valued at approximately $118,000. Janney Montgomery Scott LLC acquired a new position in Amneal Pharmaceuticals in the fourth quarter valued at approximately $121,000. Finally, Fox Run Management L.L.C. grew its holdings in shares of Amneal Pharmaceuticals by 69.0% during the 4th quarter. Fox Run Management L.L.C. now owns 20,435 shares of the company's stock worth $162,000 after purchasing an additional 8,342 shares during the period. Institutional investors and hedge funds own 31.82% of the company's stock.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Barclays boosted their price objective on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the company an "overweight" rating in a report on Monday, March 3rd. JPMorgan Chase & Co. upgraded shares of Amneal Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their target price for the stock from $9.00 to $12.00 in a research note on Monday, February 24th. Finally, StockNews.com upgraded shares of Amneal Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Monday. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $10.80.

Insider Buying and Selling

In other news, Director Gautam Patel sold 80,000 shares of the business's stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $8.90, for a total transaction of $712,000.00. Following the sale, the director now directly owns 1,808,886 shares of the company's stock, valued at $16,099,085.40. The trade was a 4.24 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the company's stock in a transaction dated Friday, March 14th. The shares were sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the sale, the insider now directly owns 48,578,209 shares of the company's stock, valued at $405,628,045.15. This represents a 9.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 26.56% of the stock is owned by company insiders.

Amneal Pharmaceuticals Trading Up 0.1 %

Shares of AMRX traded up $0.01 during mid-day trading on Tuesday, reaching $7.55. The company had a trading volume of 228,326 shares, compared to its average volume of 1,415,334. The firm has a fifty day simple moving average of $8.01 and a 200-day simple moving average of $8.15. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $6.29 and a fifty-two week high of $9.48. The stock has a market cap of $2.34 billion, a price-to-earnings ratio of -11.08 and a beta of 1.17.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last released its quarterly earnings results on Friday, May 2nd. The company reported $0.19 earnings per share for the quarter, topping analysts' consensus estimates of $0.14 by $0.05. The firm had revenue of $695.42 million during the quarter, compared to analysts' expectations of $714.78 million. Amneal Pharmaceuticals had a negative return on equity of 346.26% and a negative net margin of 6.88%. As a group, equities analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 EPS for the current fiscal year.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.